Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Glycomimetics Inc (GLYC)

Glycomimetics Inc (GLYC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
GlycoMimetics: Q4 Earnings Snapshot

GlycoMimetics: Q4 Earnings Snapshot

GLYC : 2.16 (-5.26%)
GlycoMimetics: Q3 Earnings Snapshot

GlycoMimetics: Q3 Earnings Snapshot

GLYC : 2.16 (-5.26%)
GlycoMimetics: Q2 Earnings Snapshot

GlycoMimetics: Q2 Earnings Snapshot

GLYC : 2.16 (-5.26%)
GlycoMimetics: Q1 Earnings Snapshot

GlycoMimetics: Q1 Earnings Snapshot

GLYC : 2.16 (-5.26%)
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023

GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial...

GLYC : 2.16 (-5.26%)
GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2023 financial results on Wednesday, May 3, 2023, at 8:30 a.m. ET.

GLYC : 2.16 (-5.26%)
GlycoMimetics: Q4 Earnings Snapshot

GlycoMimetics: Q4 Earnings Snapshot

GLYC : 2.16 (-5.26%)
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022

GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial...

GLYC : 2.16 (-5.26%)
GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2022 full year financial results on Wednesday, March 29, 2023, at 8:30 a.m....

GLYC : 2.16 (-5.26%)
GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 43 rd Annual Health Care Conference in Boston, MA...

GLYC : 2.16 (-5.26%)

Barchart Exclusives

2 Top Defense Stocks That Just Won New Army Contracts
Flaring tensions in the Middle East have put the spotlight on defense stocks, and even the cautious analysts at Morgan Stanley name these two picks as their top choices. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar